nodes	percent_of_prediction	percent_of_DWPC	metapath
Raltegravir—UGT1A1—hematologic cancer	0.463	1	CbGaD
Raltegravir—UGT1A1—Nilotinib—hematologic cancer	0.0893	0.447	CbGbCtD
Raltegravir—UGT1A1—Irinotecan—hematologic cancer	0.0614	0.307	CbGbCtD
Raltegravir—UGT1A1—Etoposide—hematologic cancer	0.0492	0.246	CbGbCtD
Raltegravir—CCR1—hematopoietic system—hematologic cancer	0.00776	0.252	CbGeAlD
Raltegravir—CCR1—blood—hematologic cancer	0.00514	0.167	CbGeAlD
Raltegravir—CCR1—bone marrow—hematologic cancer	0.00498	0.162	CbGeAlD
Raltegravir—CCR1—lung—hematologic cancer	0.00451	0.146	CbGeAlD
Raltegravir—UGT1A1—hematopoietic system—hematologic cancer	0.00319	0.104	CbGeAlD
Raltegravir—CCR1—lymph node—hematologic cancer	0.00308	0.1	CbGeAlD
Raltegravir—UGT1A1—blood—hematologic cancer	0.00211	0.0687	CbGeAlD
Raltegravir—CCR1—Signaling Pathways—ARHGEF12—hematologic cancer	0.000149	0.0021	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—ADCY7—hematologic cancer	0.000149	0.0021	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—PTHLH—hematologic cancer	0.000149	0.00209	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—ARHGEF1—hematologic cancer	0.000145	0.00205	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—PTGER4—hematologic cancer	0.000145	0.00204	CbGpPWpGaD
Raltegravir—UGT1A1—Phase II conjugation—GSTP1—hematologic cancer	0.000141	0.00198	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—CCL3—hematologic cancer	0.000136	0.00192	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—PTHLH—hematologic cancer	0.000135	0.0019	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—PTGER4—hematologic cancer	0.000131	0.00185	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—AGRN—hematologic cancer	0.00013	0.00184	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CCL17—hematologic cancer	0.00013	0.00184	CbGpPWpGaD
Raltegravir—UGT1A1—Phase II conjugation—GSTM1—hematologic cancer	0.000129	0.00182	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CXCR5—hematologic cancer	0.000128	0.0018	CbGpPWpGaD
Raltegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—IFNG—hematologic cancer	0.000128	0.0018	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—CXCR4—hematologic cancer	0.000128	0.0018	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—LEF1—hematologic cancer	0.000126	0.00177	CbGpPWpGaD
Raltegravir—UGT1A1—Biological oxidations—MTR—hematologic cancer	0.000125	0.00176	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—GNA13—hematologic cancer	0.000124	0.00174	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—IL3—hematologic cancer	0.000123	0.00173	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—TIAM1—hematologic cancer	0.000122	0.00171	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—RASGRP1—hematologic cancer	0.000119	0.00168	CbGpPWpGaD
Raltegravir—UGT1A1—Biological oxidations—GSTT1—hematologic cancer	0.000119	0.00167	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—CCL2—hematologic cancer	0.000118	0.00167	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—JAK3—hematologic cancer	0.000118	0.00166	CbGpPWpGaD
Raltegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—CDKN1B—hematologic cancer	0.000116	0.00164	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—CXCR4—hematologic cancer	0.000116	0.00163	CbGpPWpGaD
Raltegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—IL1B—hematologic cancer	0.000114	0.00161	CbGpPWpGaD
Raltegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—IL2—hematologic cancer	0.000114	0.0016	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CCR7—hematologic cancer	0.000113	0.00159	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CXCL13—hematologic cancer	0.000113	0.00159	CbGpPWpGaD
Raltegravir—UGT1A1—NRF2 pathway—NQO1—hematologic cancer	0.000113	0.00159	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—IL3—hematologic cancer	0.000112	0.00158	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—NCOR2—hematologic cancer	0.000112	0.00157	CbGpPWpGaD
Raltegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—JUN—hematologic cancer	0.000111	0.00156	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—IL3RA—hematologic cancer	0.00011	0.00155	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CRKL—hematologic cancer	0.00011	0.00155	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—RASGRP1—hematologic cancer	0.000108	0.00152	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—GRB2—hematologic cancer	0.000107	0.00151	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—RGS2—hematologic cancer	0.000106	0.0015	CbGpPWpGaD
Raltegravir—UGT1A1—NRF2 pathway—HSP90AA1—hematologic cancer	0.000106	0.00149	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CMA1—hematologic cancer	0.000105	0.00148	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—TRH—hematologic cancer	0.000105	0.00148	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—TRIO—hematologic cancer	0.000105	0.00148	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—AGO2—hematologic cancer	0.000103	0.00145	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—SPHK1—hematologic cancer	0.000103	0.00145	CbGpPWpGaD
Raltegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—EP300—hematologic cancer	0.000102	0.00144	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—LPAR1—hematologic cancer	0.000102	0.00143	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—HDAC9—hematologic cancer	0.000102	0.00143	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—H3F3B—hematologic cancer	0.000101	0.00142	CbGpPWpGaD
Raltegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—SRC—hematologic cancer	9.91e-05	0.0014	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—GRB2—hematologic cancer	9.73e-05	0.00137	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—CSF2—hematologic cancer	9.57e-05	0.00135	CbGpPWpGaD
Raltegravir—UGT1A1—NRF2 pathway—GSTP1—hematologic cancer	9.39e-05	0.00132	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—PDE4B—hematologic cancer	9.37e-05	0.00132	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CNR2—hematologic cancer	9.37e-05	0.00132	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—FGF19—hematologic cancer	9.29e-05	0.00131	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—JAK1—hematologic cancer	9.24e-05	0.0013	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—PRKCG—hematologic cancer	9.24e-05	0.0013	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—RAC2—hematologic cancer	9.22e-05	0.0013	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—DKK1—hematologic cancer	9.15e-05	0.00129	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—STAT5B—hematologic cancer	9.07e-05	0.00128	CbGpPWpGaD
Raltegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—TGFB1—hematologic cancer	8.86e-05	0.00125	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—ADCY7—hematologic cancer	8.81e-05	0.00124	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—CSF2—hematologic cancer	8.69e-05	0.00122	CbGpPWpGaD
Raltegravir—UGT1A1—NRF2 pathway—GSTM1—hematologic cancer	8.63e-05	0.00122	CbGpPWpGaD
Raltegravir—UGT1A1—NRF2 pathway—HGF—hematologic cancer	8.63e-05	0.00122	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—IL2RA—hematologic cancer	8.63e-05	0.00122	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—XIAP—hematologic cancer	8.57e-05	0.00121	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—JAK1—hematologic cancer	8.39e-05	0.00118	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—PRKCG—hematologic cancer	8.39e-05	0.00118	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—SH2B3—hematologic cancer	8.35e-05	0.00118	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—SMARCA4—hematologic cancer	8.35e-05	0.00118	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—GZMB—hematologic cancer	8.3e-05	0.00117	CbGpPWpGaD
Raltegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—TNF—hematologic cancer	8.27e-05	0.00117	CbGpPWpGaD
Raltegravir—UGT1A1—Biological oxidations—GSTP1—hematologic cancer	8.24e-05	0.00116	CbGpPWpGaD
Raltegravir—UGT1A1—Metapathway biotransformation—GSTP1—hematologic cancer	8.12e-05	0.00114	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CTNNA1—hematologic cancer	8.1e-05	0.00114	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—HSPB1—hematologic cancer	8.06e-05	0.00113	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—EIF4EBP1—hematologic cancer	8.06e-05	0.00113	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CCL3—hematologic cancer	8.06e-05	0.00113	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—PTHLH—hematologic cancer	7.97e-05	0.00112	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—SDC1—hematologic cancer	7.97e-05	0.00112	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—IL2RA—hematologic cancer	7.83e-05	0.0011	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—PTGER4—hematologic cancer	7.76e-05	0.00109	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—LCK—hematologic cancer	7.72e-05	0.00109	CbGpPWpGaD
Raltegravir—UGT1A1—Biological oxidations—GSTM1—hematologic cancer	7.57e-05	0.00107	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—H3F3A—hematologic cancer	7.56e-05	0.00107	CbGpPWpGaD
Raltegravir—UGT1A1—Metapathway biotransformation—GSTM1—hematologic cancer	7.46e-05	0.00105	CbGpPWpGaD
Raltegravir—UGT1A1—NRF2 pathway—PDGFB—hematologic cancer	7.42e-05	0.00105	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—PRKCZ—hematologic cancer	7.35e-05	0.00104	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—PIK3CG—hematologic cancer	7.19e-05	0.00101	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—PARP1—hematologic cancer	7.1e-05	0.001	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—FBXW7—hematologic cancer	6.99e-05	0.000984	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—HDAC2—hematologic cancer	6.85e-05	0.000965	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CXCR4—hematologic cancer	6.85e-05	0.000965	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CBL—hematologic cancer	6.68e-05	0.00094	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—IL3—hematologic cancer	6.61e-05	0.000931	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—PIK3CG—hematologic cancer	6.53e-05	0.000919	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—PTPN1—hematologic cancer	6.49e-05	0.000915	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—PTPN11—hematologic cancer	6.41e-05	0.000903	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—RASGRP1—hematologic cancer	6.39e-05	0.0009	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—HSP90AA1—hematologic cancer	6.37e-05	0.000897	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—SYK—hematologic cancer	6.37e-05	0.000897	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—PIK3CD—hematologic cancer	6.32e-05	0.00089	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—FTCD—hematologic cancer	6.31e-05	0.000889	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—PHYH—hematologic cancer	6.31e-05	0.000889	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—GMPS—hematologic cancer	6.31e-05	0.000889	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—CREB1—hematologic cancer	6.21e-05	0.000875	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—STAT1—hematologic cancer	6.14e-05	0.000865	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—CCL2—hematologic cancer	6.08e-05	0.000856	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—IL6R—hematologic cancer	6.06e-05	0.000854	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—PIK3R1—hematologic cancer	5.97e-05	0.00084	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—JAK2—hematologic cancer	5.8e-05	0.000817	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—MAP2K1—hematologic cancer	5.78e-05	0.000814	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—SMPD3—hematologic cancer	5.77e-05	0.000813	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—GRB2—hematologic cancer	5.75e-05	0.000809	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—PIK3CD—hematologic cancer	5.74e-05	0.000808	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—PDGFA—hematologic cancer	5.73e-05	0.000807	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—KITLG—hematologic cancer	5.65e-05	0.000796	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—STAT5A—hematologic cancer	5.52e-05	0.000778	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—PIK3CB—hematologic cancer	5.51e-05	0.000776	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CDKN2B—hematologic cancer	5.47e-05	0.000771	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—PIK3R1—hematologic cancer	5.42e-05	0.000763	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CD86—hematologic cancer	5.29e-05	0.000746	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—JAK2—hematologic cancer	5.27e-05	0.000742	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—HES1—hematologic cancer	5.22e-05	0.000736	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—NCOR1—hematologic cancer	5.19e-05	0.000731	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—FGF1—hematologic cancer	5.13e-05	0.000723	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CSF2—hematologic cancer	5.13e-05	0.000723	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—FOXO1—hematologic cancer	5.06e-05	0.000713	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—IL2—hematologic cancer	5.06e-05	0.000712	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—PDGFRB—hematologic cancer	5.05e-05	0.000711	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—DCK—hematologic cancer	5.05e-05	0.000711	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—B3GAT1—hematologic cancer	5.05e-05	0.000711	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—ASNS—hematologic cancer	5.05e-05	0.000711	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—PIK3CB—hematologic cancer	5e-05	0.000704	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—PDGFRA—hematologic cancer	4.97e-05	0.0007	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—JAK1—hematologic cancer	4.96e-05	0.000698	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—PRKCG—hematologic cancer	4.96e-05	0.000698	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—HDC—hematologic cancer	4.78e-05	0.000674	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—IL2RA—hematologic cancer	4.63e-05	0.000652	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—IL2—hematologic cancer	4.59e-05	0.000647	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—TERT—hematologic cancer	4.58e-05	0.000645	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—PDGFB—hematologic cancer	4.47e-05	0.000629	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—CDA—hematologic cancer	4.37e-05	0.000616	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—TSC2—hematologic cancer	4.37e-05	0.000615	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—PC—hematologic cancer	4.21e-05	0.000593	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—FGFR3—hematologic cancer	4.2e-05	0.000592	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—MAPK14—hematologic cancer	4.16e-05	0.000586	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—ESR1—hematologic cancer	4.08e-05	0.000575	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—GBA—hematologic cancer	4.07e-05	0.000573	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—SLC35B2—hematologic cancer	4.07e-05	0.000573	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—FN1—hematologic cancer	4.03e-05	0.000567	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—NFKBIA—hematologic cancer	3.98e-05	0.000561	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—BAD—hematologic cancer	3.98e-05	0.000561	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—NOTCH1—hematologic cancer	3.94e-05	0.000555	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CD80—hematologic cancer	3.86e-05	0.000544	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—PIK3CG—hematologic cancer	3.86e-05	0.000543	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—KIT—hematologic cancer	3.86e-05	0.000543	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—NRAS—hematologic cancer	3.86e-05	0.000543	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—PTPN11—hematologic cancer	3.79e-05	0.000534	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—MTAP—hematologic cancer	3.72e-05	0.000524	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—MAPK3—hematologic cancer	3.69e-05	0.00052	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CREB1—hematologic cancer	3.67e-05	0.000517	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—BRAF—hematologic cancer	3.62e-05	0.00051	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CCL2—hematologic cancer	3.59e-05	0.000506	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—IL6R—hematologic cancer	3.58e-05	0.000504	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CREBBP—hematologic cancer	3.57e-05	0.000504	CbGpPWpGaD
Raltegravir—UGT1A1—NRF2 pathway—TGFB1—hematologic cancer	3.52e-05	0.000495	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—MAP2K1—hematologic cancer	3.41e-05	0.000481	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—PIK3CD—hematologic cancer	3.39e-05	0.000477	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—PIK3CA—hematologic cancer	3.36e-05	0.000473	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—KRAS—hematologic cancer	3.32e-05	0.000467	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—FHL2—hematologic cancer	3.32e-05	0.000467	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—AGRN—hematologic cancer	3.25e-05	0.000458	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—FGF2—hematologic cancer	3.25e-05	0.000457	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—PIK3R1—hematologic cancer	3.2e-05	0.000451	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—JAK2—hematologic cancer	3.11e-05	0.000438	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—IDH2—hematologic cancer	3.08e-05	0.000434	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—HMMR—hematologic cancer	3.08e-05	0.000434	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—PIK3CA—hematologic cancer	3.05e-05	0.000429	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—MDM2—hematologic cancer	3.04e-05	0.000428	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—MTOR—hematologic cancer	2.95e-05	0.000416	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—PIK3CB—hematologic cancer	2.95e-05	0.000416	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—ARNTL—hematologic cancer	2.9e-05	0.000408	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—HRAS—hematologic cancer	2.82e-05	0.000397	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—CA9—hematologic cancer	2.82e-05	0.000397	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—ACP5—hematologic cancer	2.82e-05	0.000397	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—NCOR2—hematologic cancer	2.78e-05	0.000392	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CDKN1B—hematologic cancer	2.77e-05	0.000391	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—AKT1—hematologic cancer	2.74e-05	0.000386	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CASP3—hematologic cancer	2.72e-05	0.000383	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—IL2—hematologic cancer	2.71e-05	0.000382	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—IL6—hematologic cancer	2.7e-05	0.00038	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—IDH1—hematologic cancer	2.65e-05	0.000373	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CCND1—hematologic cancer	2.64e-05	0.000373	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—JUN—hematologic cancer	2.64e-05	0.000372	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—GSTO1—hematologic cancer	2.62e-05	0.000369	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—TXN—hematologic cancer	2.62e-05	0.000369	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—ABCC3—hematologic cancer	2.62e-05	0.000369	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—SPHK1—hematologic cancer	2.56e-05	0.000361	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CDKN1A—hematologic cancer	2.56e-05	0.00036	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—PTEN—hematologic cancer	2.55e-05	0.00036	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—MAPK8—hematologic cancer	2.5e-05	0.000352	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—AKT1—hematologic cancer	2.49e-05	0.000351	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—EP300—hematologic cancer	2.43e-05	0.000343	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—SLC22A1—hematologic cancer	2.4e-05	0.000338	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—CRABP1—hematologic cancer	2.4e-05	0.000338	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—SRC—hematologic cancer	2.37e-05	0.000333	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—ALOX5—hematologic cancer	2.34e-05	0.000329	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—VEGFA—hematologic cancer	2.31e-05	0.000325	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—STAT3—hematologic cancer	2.28e-05	0.000322	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—NRAS—hematologic cancer	2.28e-05	0.000321	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—NUP98—hematologic cancer	2.26e-05	0.000319	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—ADCY7—hematologic cancer	2.2e-05	0.000309	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—NCOA3—hematologic cancer	2.2e-05	0.000309	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—MAPK3—hematologic cancer	2.18e-05	0.000307	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—NUP214—hematologic cancer	2.18e-05	0.000307	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—ABCG2—hematologic cancer	2.14e-05	0.000301	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—MTR—hematologic cancer	2.14e-05	0.000301	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—MYC—hematologic cancer	2.12e-05	0.000299	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—TGFB1—hematologic cancer	2.12e-05	0.000298	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—ENO2—hematologic cancer	2.1e-05	0.000295	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—GSTT1—hematologic cancer	2.03e-05	0.000286	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—SDC1—hematologic cancer	1.99e-05	0.00028	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—KRAS—hematologic cancer	1.96e-05	0.000276	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—PIK3CA—hematologic cancer	1.8e-05	0.000254	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—TP53—hematologic cancer	1.74e-05	0.000245	CbGpPWpGaD
Raltegravir—Nausea—Mitoxantrone—hematologic cancer	1.72e-05	7.31e-05	CcSEcCtD
Raltegravir—Nausea—Irinotecan—hematologic cancer	1.72e-05	7.31e-05	CcSEcCtD
Raltegravir—Immune system disorder—Epirubicin—hematologic cancer	1.71e-05	7.3e-05	CcSEcCtD
Raltegravir—Infection—Prednisone—hematologic cancer	1.71e-05	7.29e-05	CcSEcCtD
Raltegravir—Mediastinal disorder—Epirubicin—hematologic cancer	1.71e-05	7.28e-05	CcSEcCtD
Raltegravir—Gastrointestinal disorder—Dexamethasone—hematologic cancer	1.71e-05	7.28e-05	CcSEcCtD
Raltegravir—Gastrointestinal disorder—Betamethasone—hematologic cancer	1.71e-05	7.28e-05	CcSEcCtD
Raltegravir—Back pain—Methotrexate—hematologic cancer	1.71e-05	7.27e-05	CcSEcCtD
Raltegravir—Fatigue—Betamethasone—hematologic cancer	1.71e-05	7.27e-05	CcSEcCtD
Raltegravir—Fatigue—Dexamethasone—hematologic cancer	1.71e-05	7.27e-05	CcSEcCtD
Raltegravir—Chills—Epirubicin—hematologic cancer	1.7e-05	7.25e-05	CcSEcCtD
Raltegravir—Pruritus—Etoposide—hematologic cancer	1.7e-05	7.24e-05	CcSEcCtD
Raltegravir—Pain—Dexamethasone—hematologic cancer	1.69e-05	7.21e-05	CcSEcCtD
Raltegravir—Pain—Betamethasone—hematologic cancer	1.69e-05	7.21e-05	CcSEcCtD
Raltegravir—Visual impairment—Doxorubicin—hematologic cancer	1.69e-05	7.2e-05	CcSEcCtD
Raltegravir—Nervous system disorder—Prednisone—hematologic cancer	1.69e-05	7.2e-05	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—NQO1—hematologic cancer	1.69e-05	0.000238	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—CD44—hematologic cancer	1.69e-05	0.000238	CbGpPWpGaD
Raltegravir—Alopecia—Epirubicin—hematologic cancer	1.68e-05	7.14e-05	CcSEcCtD
Raltegravir—Skin disorder—Prednisone—hematologic cancer	1.67e-05	7.13e-05	CcSEcCtD
Raltegravir—Nausea—Gemcitabine—hematologic cancer	1.67e-05	7.12e-05	CcSEcCtD
Raltegravir—Vomiting—Cisplatin—hematologic cancer	1.67e-05	7.11e-05	CcSEcCtD
Raltegravir—Hyperhidrosis—Prednisone—hematologic cancer	1.67e-05	7.1e-05	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—HRAS—hematologic cancer	1.67e-05	0.000235	CbGpPWpGaD
Raltegravir—Mental disorder—Epirubicin—hematologic cancer	1.66e-05	7.08e-05	CcSEcCtD
Raltegravir—Erythema multiforme—Doxorubicin—hematologic cancer	1.66e-05	7.07e-05	CcSEcCtD
Raltegravir—Rash—Cisplatin—hematologic cancer	1.66e-05	7.05e-05	CcSEcCtD
Raltegravir—Dermatitis—Cisplatin—hematologic cancer	1.65e-05	7.04e-05	CcSEcCtD
Raltegravir—Erythema—Epirubicin—hematologic cancer	1.65e-05	7.03e-05	CcSEcCtD
Raltegravir—Malnutrition—Epirubicin—hematologic cancer	1.65e-05	7.03e-05	CcSEcCtD
Raltegravir—Diarrhoea—Etoposide—hematologic cancer	1.65e-05	7.01e-05	CcSEcCtD
Raltegravir—Eye disorder—Doxorubicin—hematologic cancer	1.64e-05	6.99e-05	CcSEcCtD
Raltegravir—Ill-defined disorder—Methotrexate—hematologic cancer	1.64e-05	6.97e-05	CcSEcCtD
Raltegravir—Tinnitus—Doxorubicin—hematologic cancer	1.64e-05	6.97e-05	CcSEcCtD
Raltegravir—Anaemia—Methotrexate—hematologic cancer	1.63e-05	6.95e-05	CcSEcCtD
Raltegravir—Feeling abnormal—Betamethasone—hematologic cancer	1.63e-05	6.94e-05	CcSEcCtD
Raltegravir—Feeling abnormal—Dexamethasone—hematologic cancer	1.63e-05	6.94e-05	CcSEcCtD
Raltegravir—Cardiac disorder—Doxorubicin—hematologic cancer	1.63e-05	6.94e-05	CcSEcCtD
Raltegravir—Flatulence—Epirubicin—hematologic cancer	1.63e-05	6.93e-05	CcSEcCtD
Raltegravir—Gastrointestinal pain—Betamethasone—hematologic cancer	1.62e-05	6.89e-05	CcSEcCtD
Raltegravir—Gastrointestinal pain—Dexamethasone—hematologic cancer	1.62e-05	6.89e-05	CcSEcCtD
Raltegravir—Dysgeusia—Epirubicin—hematologic cancer	1.62e-05	6.89e-05	CcSEcCtD
Raltegravir—Hypersensitivity—Triamcinolone—hematologic cancer	1.61e-05	6.84e-05	CcSEcCtD
Raltegravir—Nervousness—Epirubicin—hematologic cancer	1.6e-05	6.83e-05	CcSEcCtD
Raltegravir—Back pain—Epirubicin—hematologic cancer	1.6e-05	6.8e-05	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—CYCS—hematologic cancer	1.6e-05	0.000225	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—IL6—hematologic cancer	1.59e-05	0.000225	CbGpPWpGaD
Raltegravir—Angiopathy—Doxorubicin—hematologic cancer	1.59e-05	6.78e-05	CcSEcCtD
Raltegravir—Malaise—Methotrexate—hematologic cancer	1.59e-05	6.78e-05	CcSEcCtD
Raltegravir—Dizziness—Etoposide—hematologic cancer	1.59e-05	6.77e-05	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—HSP90AA1—hematologic cancer	1.59e-05	0.000224	CbGpPWpGaD
Raltegravir—Immune system disorder—Doxorubicin—hematologic cancer	1.59e-05	6.75e-05	CcSEcCtD
Raltegravir—Vertigo—Methotrexate—hematologic cancer	1.59e-05	6.75e-05	CcSEcCtD
Raltegravir—Mediastinal disorder—Doxorubicin—hematologic cancer	1.58e-05	6.74e-05	CcSEcCtD
Raltegravir—Chills—Doxorubicin—hematologic cancer	1.58e-05	6.71e-05	CcSEcCtD
Raltegravir—Urticaria—Dexamethasone—hematologic cancer	1.57e-05	6.7e-05	CcSEcCtD
Raltegravir—Urticaria—Betamethasone—hematologic cancer	1.57e-05	6.7e-05	CcSEcCtD
Raltegravir—Musculoskeletal discomfort—Prednisone—hematologic cancer	1.57e-05	6.69e-05	CcSEcCtD
Raltegravir—Dizziness—Prednisolone—hematologic cancer	1.57e-05	6.68e-05	CcSEcCtD
Raltegravir—Asthenia—Triamcinolone—hematologic cancer	1.57e-05	6.66e-05	CcSEcCtD
Raltegravir—Abdominal pain—Dexamethasone—hematologic cancer	1.56e-05	6.66e-05	CcSEcCtD
Raltegravir—Body temperature increased—Dexamethasone—hematologic cancer	1.56e-05	6.66e-05	CcSEcCtD
Raltegravir—Abdominal pain—Betamethasone—hematologic cancer	1.56e-05	6.66e-05	CcSEcCtD
Raltegravir—Body temperature increased—Betamethasone—hematologic cancer	1.56e-05	6.66e-05	CcSEcCtD
Raltegravir—Nausea—Cisplatin—hematologic cancer	1.56e-05	6.64e-05	CcSEcCtD
Raltegravir—Insomnia—Prednisone—hematologic cancer	1.56e-05	6.64e-05	CcSEcCtD
Raltegravir—Alopecia—Doxorubicin—hematologic cancer	1.55e-05	6.61e-05	CcSEcCtD
Raltegravir—Paraesthesia—Prednisone—hematologic cancer	1.55e-05	6.59e-05	CcSEcCtD
Raltegravir—Pruritus—Triamcinolone—hematologic cancer	1.54e-05	6.57e-05	CcSEcCtD
Raltegravir—Cough—Methotrexate—hematologic cancer	1.54e-05	6.56e-05	CcSEcCtD
Raltegravir—Mental disorder—Doxorubicin—hematologic cancer	1.54e-05	6.55e-05	CcSEcCtD
Raltegravir—Ill-defined disorder—Epirubicin—hematologic cancer	1.53e-05	6.53e-05	CcSEcCtD
Raltegravir—Vomiting—Etoposide—hematologic cancer	1.53e-05	6.51e-05	CcSEcCtD
Raltegravir—Erythema—Doxorubicin—hematologic cancer	1.53e-05	6.51e-05	CcSEcCtD
Raltegravir—Malnutrition—Doxorubicin—hematologic cancer	1.53e-05	6.51e-05	CcSEcCtD
Raltegravir—Anaemia—Epirubicin—hematologic cancer	1.53e-05	6.5e-05	CcSEcCtD
Raltegravir—Agitation—Epirubicin—hematologic cancer	1.52e-05	6.46e-05	CcSEcCtD
Raltegravir—Dyspepsia—Prednisone—hematologic cancer	1.52e-05	6.46e-05	CcSEcCtD
Raltegravir—Rash—Etoposide—hematologic cancer	1.52e-05	6.46e-05	CcSEcCtD
Raltegravir—Dermatitis—Etoposide—hematologic cancer	1.52e-05	6.45e-05	CcSEcCtD
Raltegravir—Headache—Etoposide—hematologic cancer	1.51e-05	6.42e-05	CcSEcCtD
Raltegravir—Flatulence—Doxorubicin—hematologic cancer	1.51e-05	6.41e-05	CcSEcCtD
Raltegravir—Chest pain—Methotrexate—hematologic cancer	1.5e-05	6.4e-05	CcSEcCtD
Raltegravir—Myalgia—Methotrexate—hematologic cancer	1.5e-05	6.4e-05	CcSEcCtD
Raltegravir—Arthralgia—Methotrexate—hematologic cancer	1.5e-05	6.4e-05	CcSEcCtD
Raltegravir—Decreased appetite—Prednisone—hematologic cancer	1.5e-05	6.38e-05	CcSEcCtD
Raltegravir—Dysgeusia—Doxorubicin—hematologic cancer	1.5e-05	6.37e-05	CcSEcCtD
Raltegravir—Rash—Prednisolone—hematologic cancer	1.5e-05	6.37e-05	CcSEcCtD
Raltegravir—Dermatitis—Prednisolone—hematologic cancer	1.49e-05	6.36e-05	CcSEcCtD
Raltegravir—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	1.49e-05	6.35e-05	CcSEcCtD
Raltegravir—Malaise—Epirubicin—hematologic cancer	1.49e-05	6.34e-05	CcSEcCtD
Raltegravir—Fatigue—Prednisone—hematologic cancer	1.49e-05	6.33e-05	CcSEcCtD
Raltegravir—Headache—Prednisolone—hematologic cancer	1.49e-05	6.33e-05	CcSEcCtD
Raltegravir—Discomfort—Methotrexate—hematologic cancer	1.48e-05	6.32e-05	CcSEcCtD
Raltegravir—Nervousness—Doxorubicin—hematologic cancer	1.48e-05	6.32e-05	CcSEcCtD
Raltegravir—Vertigo—Epirubicin—hematologic cancer	1.48e-05	6.32e-05	CcSEcCtD
Raltegravir—Back pain—Doxorubicin—hematologic cancer	1.48e-05	6.29e-05	CcSEcCtD
Raltegravir—Constipation—Prednisone—hematologic cancer	1.47e-05	6.28e-05	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—AKT1—hematologic cancer	1.47e-05	0.000207	CbGpPWpGaD
Raltegravir—Palpitations—Epirubicin—hematologic cancer	1.46e-05	6.22e-05	CcSEcCtD
Raltegravir—Confusional state—Methotrexate—hematologic cancer	1.45e-05	6.18e-05	CcSEcCtD
Raltegravir—Dizziness—Triamcinolone—hematologic cancer	1.44e-05	6.14e-05	CcSEcCtD
Raltegravir—Cough—Epirubicin—hematologic cancer	1.44e-05	6.14e-05	CcSEcCtD
Raltegravir—Infection—Methotrexate—hematologic cancer	1.43e-05	6.09e-05	CcSEcCtD
Raltegravir—Nausea—Etoposide—hematologic cancer	1.43e-05	6.08e-05	CcSEcCtD
Raltegravir—Hypertension—Epirubicin—hematologic cancer	1.43e-05	6.07e-05	CcSEcCtD
Raltegravir—Feeling abnormal—Prednisone—hematologic cancer	1.42e-05	6.05e-05	CcSEcCtD
Raltegravir—Asthenia—Betamethasone—hematologic cancer	1.42e-05	6.05e-05	CcSEcCtD
Raltegravir—Asthenia—Dexamethasone—hematologic cancer	1.42e-05	6.05e-05	CcSEcCtD
Raltegravir—Ill-defined disorder—Doxorubicin—hematologic cancer	1.42e-05	6.04e-05	CcSEcCtD
Raltegravir—Nervous system disorder—Methotrexate—hematologic cancer	1.41e-05	6.02e-05	CcSEcCtD
Raltegravir—Anaemia—Doxorubicin—hematologic cancer	1.41e-05	6.01e-05	CcSEcCtD
Raltegravir—Thrombocytopenia—Methotrexate—hematologic cancer	1.41e-05	6.01e-05	CcSEcCtD
Raltegravir—Gastrointestinal pain—Prednisone—hematologic cancer	1.41e-05	6e-05	CcSEcCtD
Raltegravir—Nausea—Prednisolone—hematologic cancer	1.41e-05	6e-05	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—GSTP1—hematologic cancer	1.41e-05	0.000198	CbGpPWpGaD
Raltegravir—Chest pain—Epirubicin—hematologic cancer	1.41e-05	5.99e-05	CcSEcCtD
Raltegravir—Myalgia—Epirubicin—hematologic cancer	1.41e-05	5.99e-05	CcSEcCtD
Raltegravir—Arthralgia—Epirubicin—hematologic cancer	1.41e-05	5.99e-05	CcSEcCtD
Raltegravir—Agitation—Doxorubicin—hematologic cancer	1.4e-05	5.98e-05	CcSEcCtD
Raltegravir—Anxiety—Epirubicin—hematologic cancer	1.4e-05	5.97e-05	CcSEcCtD
Raltegravir—Pruritus—Betamethasone—hematologic cancer	1.4e-05	5.96e-05	CcSEcCtD
Raltegravir—Pruritus—Dexamethasone—hematologic cancer	1.4e-05	5.96e-05	CcSEcCtD
Raltegravir—Skin disorder—Methotrexate—hematologic cancer	1.4e-05	5.96e-05	CcSEcCtD
Raltegravir—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	1.4e-05	5.95e-05	CcSEcCtD
Raltegravir—Hyperhidrosis—Methotrexate—hematologic cancer	1.39e-05	5.93e-05	CcSEcCtD
Raltegravir—Discomfort—Epirubicin—hematologic cancer	1.39e-05	5.92e-05	CcSEcCtD
Raltegravir—Vomiting—Triamcinolone—hematologic cancer	1.39e-05	5.91e-05	CcSEcCtD
Raltegravir—Malaise—Doxorubicin—hematologic cancer	1.38e-05	5.87e-05	CcSEcCtD
Raltegravir—Rash—Triamcinolone—hematologic cancer	1.38e-05	5.86e-05	CcSEcCtD
Raltegravir—Dry mouth—Epirubicin—hematologic cancer	1.38e-05	5.86e-05	CcSEcCtD
Raltegravir—Dermatitis—Triamcinolone—hematologic cancer	1.37e-05	5.85e-05	CcSEcCtD
Raltegravir—Vertigo—Doxorubicin—hematologic cancer	1.37e-05	5.85e-05	CcSEcCtD
Raltegravir—Urticaria—Prednisone—hematologic cancer	1.37e-05	5.83e-05	CcSEcCtD
Raltegravir—Headache—Triamcinolone—hematologic cancer	1.37e-05	5.82e-05	CcSEcCtD
Raltegravir—Body temperature increased—Prednisone—hematologic cancer	1.36e-05	5.8e-05	CcSEcCtD
Raltegravir—Abdominal pain—Prednisone—hematologic cancer	1.36e-05	5.8e-05	CcSEcCtD
Raltegravir—Confusional state—Epirubicin—hematologic cancer	1.36e-05	5.79e-05	CcSEcCtD
Raltegravir—Diarrhoea—Betamethasone—hematologic cancer	1.35e-05	5.77e-05	CcSEcCtD
Raltegravir—Diarrhoea—Dexamethasone—hematologic cancer	1.35e-05	5.77e-05	CcSEcCtD
Raltegravir—Palpitations—Doxorubicin—hematologic cancer	1.35e-05	5.75e-05	CcSEcCtD
Raltegravir—Infection—Epirubicin—hematologic cancer	1.34e-05	5.7e-05	CcSEcCtD
Raltegravir—Cough—Doxorubicin—hematologic cancer	1.33e-05	5.68e-05	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—ABCB1—hematologic cancer	1.33e-05	0.000188	CbGpPWpGaD
Raltegravir—Nervous system disorder—Epirubicin—hematologic cancer	1.32e-05	5.63e-05	CcSEcCtD
Raltegravir—Thrombocytopenia—Epirubicin—hematologic cancer	1.32e-05	5.62e-05	CcSEcCtD
Raltegravir—Hypertension—Doxorubicin—hematologic cancer	1.32e-05	5.62e-05	CcSEcCtD
Raltegravir—Musculoskeletal discomfort—Methotrexate—hematologic cancer	1.31e-05	5.59e-05	CcSEcCtD
Raltegravir—Skin disorder—Epirubicin—hematologic cancer	1.31e-05	5.58e-05	CcSEcCtD
Raltegravir—Dizziness—Betamethasone—hematologic cancer	1.31e-05	5.57e-05	CcSEcCtD
Raltegravir—Dizziness—Dexamethasone—hematologic cancer	1.31e-05	5.57e-05	CcSEcCtD
Raltegravir—Hyperhidrosis—Epirubicin—hematologic cancer	1.3e-05	5.55e-05	CcSEcCtD
Raltegravir—Insomnia—Methotrexate—hematologic cancer	1.3e-05	5.55e-05	CcSEcCtD
Raltegravir—Arthralgia—Doxorubicin—hematologic cancer	1.3e-05	5.54e-05	CcSEcCtD
Raltegravir—Myalgia—Doxorubicin—hematologic cancer	1.3e-05	5.54e-05	CcSEcCtD
Raltegravir—Chest pain—Doxorubicin—hematologic cancer	1.3e-05	5.54e-05	CcSEcCtD
Raltegravir—Anxiety—Doxorubicin—hematologic cancer	1.3e-05	5.52e-05	CcSEcCtD
Raltegravir—Nausea—Triamcinolone—hematologic cancer	1.3e-05	5.52e-05	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—GSTM1—hematologic cancer	1.29e-05	0.000182	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—NCOR1—hematologic cancer	1.29e-05	0.000182	CbGpPWpGaD
Raltegravir—Paraesthesia—Methotrexate—hematologic cancer	1.29e-05	5.51e-05	CcSEcCtD
Raltegravir—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	1.29e-05	5.5e-05	CcSEcCtD
Raltegravir—Discomfort—Doxorubicin—hematologic cancer	1.29e-05	5.47e-05	CcSEcCtD
Raltegravir—Somnolence—Methotrexate—hematologic cancer	1.28e-05	5.45e-05	CcSEcCtD
Raltegravir—Dry mouth—Doxorubicin—hematologic cancer	1.27e-05	5.42e-05	CcSEcCtD
Raltegravir—Hypersensitivity—Prednisone—hematologic cancer	1.27e-05	5.41e-05	CcSEcCtD
Raltegravir—Dyspepsia—Methotrexate—hematologic cancer	1.27e-05	5.4e-05	CcSEcCtD
Raltegravir—Vomiting—Betamethasone—hematologic cancer	1.26e-05	5.36e-05	CcSEcCtD
Raltegravir—Vomiting—Dexamethasone—hematologic cancer	1.26e-05	5.36e-05	CcSEcCtD
Raltegravir—Confusional state—Doxorubicin—hematologic cancer	1.26e-05	5.36e-05	CcSEcCtD
Raltegravir—Decreased appetite—Methotrexate—hematologic cancer	1.25e-05	5.33e-05	CcSEcCtD
Raltegravir—Rash—Betamethasone—hematologic cancer	1.25e-05	5.31e-05	CcSEcCtD
Raltegravir—Rash—Dexamethasone—hematologic cancer	1.25e-05	5.31e-05	CcSEcCtD
Raltegravir—Dermatitis—Dexamethasone—hematologic cancer	1.25e-05	5.31e-05	CcSEcCtD
Raltegravir—Dermatitis—Betamethasone—hematologic cancer	1.25e-05	5.31e-05	CcSEcCtD
Raltegravir—Gastrointestinal disorder—Methotrexate—hematologic cancer	1.24e-05	5.3e-05	CcSEcCtD
Raltegravir—Fatigue—Methotrexate—hematologic cancer	1.24e-05	5.29e-05	CcSEcCtD
Raltegravir—Headache—Betamethasone—hematologic cancer	1.24e-05	5.28e-05	CcSEcCtD
Raltegravir—Headache—Dexamethasone—hematologic cancer	1.24e-05	5.28e-05	CcSEcCtD
Raltegravir—Infection—Doxorubicin—hematologic cancer	1.24e-05	5.28e-05	CcSEcCtD
Raltegravir—Asthenia—Prednisone—hematologic cancer	1.24e-05	5.27e-05	CcSEcCtD
Raltegravir—Pain—Methotrexate—hematologic cancer	1.23e-05	5.25e-05	CcSEcCtD
Raltegravir—Musculoskeletal discomfort—Epirubicin—hematologic cancer	1.23e-05	5.23e-05	CcSEcCtD
Raltegravir—Nervous system disorder—Doxorubicin—hematologic cancer	1.22e-05	5.21e-05	CcSEcCtD
Raltegravir—Thrombocytopenia—Doxorubicin—hematologic cancer	1.22e-05	5.2e-05	CcSEcCtD
Raltegravir—Pruritus—Prednisone—hematologic cancer	1.22e-05	5.19e-05	CcSEcCtD
Raltegravir—Insomnia—Epirubicin—hematologic cancer	1.22e-05	5.19e-05	CcSEcCtD
Raltegravir—Skin disorder—Doxorubicin—hematologic cancer	1.21e-05	5.16e-05	CcSEcCtD
Raltegravir—Paraesthesia—Epirubicin—hematologic cancer	1.21e-05	5.15e-05	CcSEcCtD
Raltegravir—Hyperhidrosis—Doxorubicin—hematologic cancer	1.21e-05	5.13e-05	CcSEcCtD
Raltegravir—Somnolence—Epirubicin—hematologic cancer	1.2e-05	5.1e-05	CcSEcCtD
Raltegravir—Feeling abnormal—Methotrexate—hematologic cancer	1.19e-05	5.05e-05	CcSEcCtD
Raltegravir—Dyspepsia—Epirubicin—hematologic cancer	1.19e-05	5.05e-05	CcSEcCtD
Raltegravir—Diarrhoea—Prednisone—hematologic cancer	1.18e-05	5.02e-05	CcSEcCtD
Raltegravir—Gastrointestinal pain—Methotrexate—hematologic cancer	1.18e-05	5.02e-05	CcSEcCtD
Raltegravir—Nausea—Betamethasone—hematologic cancer	1.18e-05	5.01e-05	CcSEcCtD
Raltegravir—Nausea—Dexamethasone—hematologic cancer	1.18e-05	5.01e-05	CcSEcCtD
Raltegravir—Decreased appetite—Epirubicin—hematologic cancer	1.17e-05	4.99e-05	CcSEcCtD
Raltegravir—Gastrointestinal disorder—Epirubicin—hematologic cancer	1.16e-05	4.96e-05	CcSEcCtD
Raltegravir—Fatigue—Epirubicin—hematologic cancer	1.16e-05	4.95e-05	CcSEcCtD
Raltegravir—Pain—Epirubicin—hematologic cancer	1.15e-05	4.91e-05	CcSEcCtD
Raltegravir—Constipation—Epirubicin—hematologic cancer	1.15e-05	4.91e-05	CcSEcCtD
Raltegravir—Urticaria—Methotrexate—hematologic cancer	1.14e-05	4.87e-05	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—MTHFR—hematologic cancer	1.14e-05	0.000161	CbGpPWpGaD
Raltegravir—Dizziness—Prednisone—hematologic cancer	1.14e-05	4.85e-05	CcSEcCtD
Raltegravir—Body temperature increased—Methotrexate—hematologic cancer	1.14e-05	4.85e-05	CcSEcCtD
Raltegravir—Abdominal pain—Methotrexate—hematologic cancer	1.14e-05	4.85e-05	CcSEcCtD
Raltegravir—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	1.14e-05	4.84e-05	CcSEcCtD
Raltegravir—Insomnia—Doxorubicin—hematologic cancer	1.13e-05	4.8e-05	CcSEcCtD
Raltegravir—Paraesthesia—Doxorubicin—hematologic cancer	1.12e-05	4.77e-05	CcSEcCtD
Raltegravir—Feeling abnormal—Epirubicin—hematologic cancer	1.11e-05	4.73e-05	CcSEcCtD
Raltegravir—Somnolence—Doxorubicin—hematologic cancer	1.11e-05	4.72e-05	CcSEcCtD
Raltegravir—Gastrointestinal pain—Epirubicin—hematologic cancer	1.1e-05	4.69e-05	CcSEcCtD
Raltegravir—Dyspepsia—Doxorubicin—hematologic cancer	1.1e-05	4.68e-05	CcSEcCtD
Raltegravir—Vomiting—Prednisone—hematologic cancer	1.1e-05	4.67e-05	CcSEcCtD
Raltegravir—Rash—Prednisone—hematologic cancer	1.09e-05	4.63e-05	CcSEcCtD
Raltegravir—Dermatitis—Prednisone—hematologic cancer	1.09e-05	4.62e-05	CcSEcCtD
Raltegravir—Decreased appetite—Doxorubicin—hematologic cancer	1.08e-05	4.62e-05	CcSEcCtD
Raltegravir—Headache—Prednisone—hematologic cancer	1.08e-05	4.6e-05	CcSEcCtD
Raltegravir—Gastrointestinal disorder—Doxorubicin—hematologic cancer	1.08e-05	4.59e-05	CcSEcCtD
Raltegravir—Fatigue—Doxorubicin—hematologic cancer	1.08e-05	4.58e-05	CcSEcCtD
Raltegravir—Urticaria—Epirubicin—hematologic cancer	1.07e-05	4.56e-05	CcSEcCtD
Raltegravir—Constipation—Doxorubicin—hematologic cancer	1.07e-05	4.54e-05	CcSEcCtD
Raltegravir—Pain—Doxorubicin—hematologic cancer	1.07e-05	4.54e-05	CcSEcCtD
Raltegravir—Abdominal pain—Epirubicin—hematologic cancer	1.07e-05	4.54e-05	CcSEcCtD
Raltegravir—Body temperature increased—Epirubicin—hematologic cancer	1.07e-05	4.54e-05	CcSEcCtD
Raltegravir—Hypersensitivity—Methotrexate—hematologic cancer	1.06e-05	4.52e-05	CcSEcCtD
Raltegravir—Asthenia—Methotrexate—hematologic cancer	1.03e-05	4.4e-05	CcSEcCtD
Raltegravir—Feeling abnormal—Doxorubicin—hematologic cancer	1.03e-05	4.38e-05	CcSEcCtD
Raltegravir—Nausea—Prednisone—hematologic cancer	1.02e-05	4.36e-05	CcSEcCtD
Raltegravir—Gastrointestinal pain—Doxorubicin—hematologic cancer	1.02e-05	4.34e-05	CcSEcCtD
Raltegravir—Pruritus—Methotrexate—hematologic cancer	1.02e-05	4.34e-05	CcSEcCtD
Raltegravir—Hypersensitivity—Epirubicin—hematologic cancer	9.93e-06	4.23e-05	CcSEcCtD
Raltegravir—Urticaria—Doxorubicin—hematologic cancer	9.91e-06	4.22e-05	CcSEcCtD
Raltegravir—Abdominal pain—Doxorubicin—hematologic cancer	9.86e-06	4.2e-05	CcSEcCtD
Raltegravir—Body temperature increased—Doxorubicin—hematologic cancer	9.86e-06	4.2e-05	CcSEcCtD
Raltegravir—Diarrhoea—Methotrexate—hematologic cancer	9.86e-06	4.2e-05	CcSEcCtD
Raltegravir—Asthenia—Epirubicin—hematologic cancer	9.67e-06	4.12e-05	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—PIK3CG—hematologic cancer	9.61e-06	0.000135	CbGpPWpGaD
Raltegravir—Pruritus—Epirubicin—hematologic cancer	9.54e-06	4.06e-05	CcSEcCtD
Raltegravir—Dizziness—Methotrexate—hematologic cancer	9.53e-06	4.06e-05	CcSEcCtD
Raltegravir—Diarrhoea—Epirubicin—hematologic cancer	9.23e-06	3.93e-05	CcSEcCtD
Raltegravir—Hypersensitivity—Doxorubicin—hematologic cancer	9.19e-06	3.91e-05	CcSEcCtD
Raltegravir—Vomiting—Methotrexate—hematologic cancer	9.16e-06	3.9e-05	CcSEcCtD
Raltegravir—Rash—Methotrexate—hematologic cancer	9.08e-06	3.87e-05	CcSEcCtD
Raltegravir—Dermatitis—Methotrexate—hematologic cancer	9.08e-06	3.86e-05	CcSEcCtD
Raltegravir—Headache—Methotrexate—hematologic cancer	9.03e-06	3.84e-05	CcSEcCtD
Raltegravir—Asthenia—Doxorubicin—hematologic cancer	8.95e-06	3.81e-05	CcSEcCtD
Raltegravir—Dizziness—Epirubicin—hematologic cancer	8.92e-06	3.8e-05	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—CREBBP—hematologic cancer	8.91e-06	0.000126	CbGpPWpGaD
Raltegravir—Pruritus—Doxorubicin—hematologic cancer	8.83e-06	3.76e-05	CcSEcCtD
Raltegravir—Vomiting—Epirubicin—hematologic cancer	8.57e-06	3.65e-05	CcSEcCtD
Raltegravir—Nausea—Methotrexate—hematologic cancer	8.56e-06	3.64e-05	CcSEcCtD
Raltegravir—Diarrhoea—Doxorubicin—hematologic cancer	8.54e-06	3.63e-05	CcSEcCtD
Raltegravir—Rash—Epirubicin—hematologic cancer	8.5e-06	3.62e-05	CcSEcCtD
Raltegravir—Dermatitis—Epirubicin—hematologic cancer	8.49e-06	3.62e-05	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—PIK3CD—hematologic cancer	8.45e-06	0.000119	CbGpPWpGaD
Raltegravir—Headache—Epirubicin—hematologic cancer	8.45e-06	3.6e-05	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—ALB—hematologic cancer	8.34e-06	0.000117	CbGpPWpGaD
Raltegravir—Dizziness—Doxorubicin—hematologic cancer	8.25e-06	3.51e-05	CcSEcCtD
Raltegravir—Nausea—Epirubicin—hematologic cancer	8.01e-06	3.41e-05	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—PIK3R1—hematologic cancer	7.98e-06	0.000112	CbGpPWpGaD
Raltegravir—Vomiting—Doxorubicin—hematologic cancer	7.93e-06	3.38e-05	CcSEcCtD
Raltegravir—Rash—Doxorubicin—hematologic cancer	7.87e-06	3.35e-05	CcSEcCtD
Raltegravir—Dermatitis—Doxorubicin—hematologic cancer	7.86e-06	3.35e-05	CcSEcCtD
Raltegravir—Headache—Doxorubicin—hematologic cancer	7.82e-06	3.33e-05	CcSEcCtD
Raltegravir—Nausea—Doxorubicin—hematologic cancer	7.41e-06	3.15e-05	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—PIK3CB—hematologic cancer	7.36e-06	0.000104	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—PTEN—hematologic cancer	6.36e-06	8.96e-05	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—EP300—hematologic cancer	6.07e-06	8.55e-05	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—PIK3CA—hematologic cancer	4.49e-06	6.32e-05	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—AKT1—hematologic cancer	3.67e-06	5.17e-05	CbGpPWpGaD
